Clearmind Medicine Successfully Completes Part A of its FDA Regulated Phase I/II Trial

Clearmind Medicine announced successful completion of treatment for all 24 participants in Part A of its Phase I/II clinical trial evaluating CMND-100 for alcohol use disorder. The multicenter trial, conducted under FDA oversight at leading U.S. and Israeli research institutions, is progressing to data review with plans to advance to the next phase of development pending favorable results.